FDA Advisory Panel Opens Two-Day Review Of Seven Unapproved Peptide Therapies
An FDA advisory committee opened a two-day meeting on July 23 in Washington, D.C., to decide whether compounding pharmacies should be allowed to make seven popular unapproved peptide therapies.[1]
The committee will spend July 23-24 reviewing safety and the available evidence and will cast nonbinding votes on whether to add the seven peptides to the agency's list of substances eligible for pharmacy compounding.[2] The panel includes 20 outside advisers, at least seven of whom have financial ties to the peptide industry, and the FDA added academic experts this week to try to address conflicts of interest.[1]
During the Biden administration the FDA added nearly 20 peptides to a "do not compound" list, saying those substances posed significant safety risks because testing was limited.[3] FDA career scientists say evidence is insufficient to support compounding of peptides such as BPC-157 and TB-500, which the agency has previously warned the public about.[1] Many of the peptides under consideration are sold online as "research use only" products in a gray market that can involve contamination or impurities, and some clinicians urge keeping restrictions until stronger clinical data exist while others argue regulated clinical access is safer than the online market.[3]
Early coverage stressed safety and limited evidence, but reporting has shifted to emphasize political pressure after HHS Secretary Robert F. Kennedy Jr. publicly called himself a "big fan" of peptides and said he has used them for injuries.[3] Some former FDA officials and observers say Kennedy's stance raises doubts about whether the panel's review will be an "honest investigation" and may influence the likely outcome.[3] Safety advocates, including Rita Jew of the Institute for Safe Medication Practices, warned that allowing wider peptide access with minimal clinical data would be "really alarming." PBS
Show source details & analysis (5 sources)
📌 Key Facts
- The NPR Up First newsletter reiterated that the FDA advisory committee begins its two‑day meeting on Thursday, July 23, 2026, to consider whether compounding pharmacies should be allowed to produce seven popular peptides, noting the meeting was “starting today.” NPR Up First newsletter
- PBS News reported the FDA advisory meeting formally began on Thursday, July 23, 2026, in Washington, D.C., marking Day 1 of the scheduled two‑day session. PBS News
- The committee will spend July 23–24, 2026, reviewing safety and evidence for seven popular unapproved peptides and will vote (nonbinding) on whether to add the seven popular unapproved peptides to the agency’s list of substances eligible for pharmacy compounding. seven popular unapproved peptides
- The 20‑member outside advisory panel includes at least seven doctors or pharmacists with financial ties to the peptide industry (owners of wellness clinics, peptide‑compounding pharmacies and online consulting businesses), and FDA added additional academic experts without industry ties earlier in the week to address conflicts‑of‑interest concerns. 20‑member outside advisory panel
- HHS Secretary Robert F. Kennedy Jr. has publicly called himself a “big fan” of peptides, said he has used them for injuries, and has vowed to overturn prior restrictions — a stance that adds political pressure around the advisory meeting. HHS Secretary Robert F. Kennedy Jr.
- FDA career scientists and agency staff say there is insufficient safety and efficacy evidence to support compounding of peptides such as BPC‑157 and TB‑500, which the FDA has previously warned the public about. BPC‑157 and TB‑500
- Health experts and some clinicians publicly urged caution on July 23, 2026, saying the evidence base for these peptides is limited and many clinicians are skeptical of easing compounding restrictions before more clinical data are available. health experts
- Many of the peptides under consideration are currently sold online as “research use only” products in a gray market that can involve contamination or impurities — experts warned such products could contain toxic substances like arsenic or lead. 'research use only' products
- Proponents argue that because patients will seek these therapies anyway, the FDA should ensure they can be provided by doctors in clinical settings rather than through an online gray market; IVIM Health chief medical officer Dr. Jessica Duncan plans to testify to that effect. Dr. Jessica Duncan
📰 Source Timeline (5)
Follow how coverage of this story developed over time
- The CBS article, published Thursday, July 23, 2026, reiterates that the FDA advisory panel will spend two days weighing whether compounding pharmacies may fill prescriptions for seven unapproved peptide therapies.
- It details that HHS Secretary Robert F. Kennedy Jr. has publicly called himself a "big fan" of the unapproved peptides and said he has personally used them for injuries, underscoring political pressure around the meeting.
- The article names BPC-157 as one of the peptides under discussion and notes that NYU Langone endocrinologist Dr. Rachel Pessah-Pollack says BPC-157 has been tested in only about 30 humans, contrasting that with hundreds of thousands of patients studied for GLP-1 drugs.
- It quotes IVIM Health chief medical officer Dr. Jessica Duncan, who plans to testify before the panel, arguing that because patients will seek out these therapies, the FDA should ensure they can be provided by doctors in a clinical setting rather than in an online gray market.
- The piece highlights that many peptides are currently sold online as "research use only" products in a gray market that experts warn can involve contamination or impurities, with Pessah-Pollack cautioning that such products could contain toxic substances like arsenic or lead.
- The article notes that during the Biden administration the FDA added nearly 20 peptides to the agency's 'do not compound' list, with prior FDA language describing those substances as presenting "significant safety risks" due to limited testing, and that many of the advisers and staff involved in those decisions have since left the agency.
- Former FDA official Dr. Peter Lurie is quoted saying that, given Kennedy's public support for peptides, he doubts the upcoming advisory panel hearing will be an "honest investigation" and believes "everybody knows the outcome that the secretary wants."
- The FDA advisory meeting formally began on Thursday, July 23, 2026, in Washington, D.C., marking Day 1 of the scheduled two-day session.
- HHS Secretary Robert F. Kennedy Jr. has publicly described himself as a "big fan" of peptides and has vowed to overturn restrictions imposed under President Joe Biden, and this FDA meeting has his backing.
- The 20-member outside advisory panel includes at least seven doctors or pharmacists with financial ties to the peptide industry, such as owners of wellness clinics, peptide-compounding pharmacies, and online consulting businesses.
- Earlier in the week, FDA added additional experts without industry ties to the panel, including academics, to balance conflicts of interest concerns.
- Rita Jew, president of the Institute for Safe Medication Practices, warned that allowing wider peptide access despite minimal evidence is "really alarming" because there are few other substances people inject with such limited clinical data.
- FDA career scientists remain unconvinced there is sufficient safety and efficacy evidence to support compounding of the peptides, including BPC-157 and TB-500, which FDA has previously warned the public about.
- The committee will vote on whether seven popular peptides should be added to the agency's list of substances eligible for pharmacy compounding, though its votes will be nonbinding.
- CBS reports on July 23, 2026, that health experts are publicly urging caution about allowing compounded access to the seven peptides, citing a lack of robust research.
- The CBS segment frames the FDA’s July 23-24 advisory committee as focused on whether compounding pharmacies can dispense these seven unapproved peptides with a doctor’s prescription for special medical conditions, underscoring concern over off-label or lightly evidenced uses.
- The piece highlights that, despite growing demand for peptide therapies, some clinicians remain skeptical of easing restrictions before more clinical data are available.
- The NPR Up First newsletter reiterates that the FDA advisory committee begins its two‑day meeting on Thursday, July 23, 2026, to consider whether compounding pharmacies should be allowed to produce seven popular peptides, and frames the meeting’s start as occurring “starting today.”
- It confirms the meeting’s structure as a two‑day session in which the panel will review safety and evidence for compounding these largely unapproved peptide therapies.